- Home
- SHO vs RCKT Comparison
SHO vs RCKT Comparison
Compare SHO & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHO
- RCKT
- Stock Information
- Founded
- SHO 1995
- RCKT 1999
- Country
- SHO United States
- RCKT United States
- Employees
- SHO N/A
- RCKT N/A
- Industry
- SHO Hotels/Resorts
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- SHO Consumer Discretionary
- RCKT Health Care
- Exchange
- SHO Nasdaq
- RCKT Nasdaq
- Market Cap
- SHO 1.7B
- RCKT 264.0M
- IPO Year
- SHO 1995
- RCKT N/A
- Fundamental
- Price
- SHO $9.16
- RCKT $2.99
- Analyst Decision
- SHO Hold
- RCKT Buy
- Analyst Count
- SHO 8
- RCKT 13
- Target Price
- SHO $9.56
- RCKT $18.50
- AVG Volume (30 Days)
- SHO 2.7M
- RCKT 3.8M
- Earning Date
- SHO 08-06-2025
- RCKT 08-04-2025
- Dividend Yield
- SHO 3.89%
- RCKT N/A
- EPS Growth
- SHO N/A
- RCKT N/A
- EPS
- SHO 0.10
- RCKT N/A
- Revenue
- SHO $922,708,000.00
- RCKT N/A
- Revenue This Year
- SHO $7.67
- RCKT N/A
- Revenue Next Year
- SHO $3.45
- RCKT N/A
- P/E Ratio
- SHO $92.87
- RCKT N/A
- Revenue Growth
- SHO N/A
- RCKT N/A
- 52 Week Low
- SHO $7.45
- RCKT $2.19
- 52 Week High
- SHO $12.41
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- SHO 59.10
- RCKT 45.55
- Support Level
- SHO $8.70
- RCKT $2.76
- Resistance Level
- SHO $9.30
- RCKT $3.24
- Average True Range (ATR)
- SHO 0.24
- RCKT 0.19
- MACD
- SHO 0.04
- RCKT 0.17
- Stochastic Oscillator
- SHO 83.57
- RCKT 74.85
About SHO Sunstone Hotel Investors Inc. Sunstone Hotel Investors Inc.
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in Califiornia which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its hotel ownership segment.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.